You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
连花清瘟概念继续获资金追捧 以岭药业连续4日涨停 年内累涨204%
格隆汇 04-16 14:48
格隆汇4月16日丨近期持续强势的两只连花清瘟概念股今日继续上涨,其中,以岭药业连续4日涨停,最新报37.9元,再创历史新高价,年内累涨幅度达204%。振东制药在连续两日涨停后,今日继续上涨近7%,盘中最高价元创2018年4月以来新高。

连花清瘟近日火遍国内外,4月14日,以岭药业发布公告称,公司药品连花清瘟胶囊(颗粒)新增适应症申请获得批准,处方药说明书中增加“在新型冠状病毒性肺炎的常规治疗中,可用于轻型、普通型引起的发热、咳嗽、乏力。”这意味着,连花清瘟胶囊在疫情期间的救治临床实践正式被官方承认。 据悉,以岭药业已将其出口到加拿大、罗马尼亚、印度尼西亚、莫桑比克、巴西、泰国等地。中国工程院院士、天津中医药大学校长张伯礼15日称,泰国已经给连花清瘟颁布许可证,可以在泰国销售,法国也准备用连花清瘟做新冠肺炎治疗的临床研究。不过,此前以岭药业发公告提醒称连花清瘟胶囊在已获上市许可国家/地区销售收入占营收比重较低。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account